Brief: Immune Therapeutics Inc Announces Management Change
09/11/2022 22:14
Nov 9 (Reuters) - Immune Therapeutics Inc IMUN.PK :
* IMMUNE THERAPEUTICS, INC. ANNOUNCES MANAGEMENT CHANGE;
MOVES
FORWARD WITH REPOSITIONING STRATEGY AND LONG-ACTING TLR4 (TOLL
LIKE RECEPTOR 4) ANTAGONIST JKB-122 DEVELOPMENT
* IMMUNE THERAPEUTICS INC - CHIEF EXECUTIVE OFFICER,
PRESIDENT,
AND DIRECTOR, STEPHEN WILSON, PHD, RESIGNED FROM HIS POSITIONS
* IMMUNE THERAPEUTICS INC - BOARD HAS COMMENCED A SEARCH FOR
A
REPLACEMENT CEO
* IMMUNE THERAPEUTICS INC - FOR REMAINDER OF YEAR, KELLY
WILSON
WILL FILL ROLES OF INTERIM CHIEF EXECUTIVE OFFICER AND INTERIM
PRESIDENT
* IMMUNE THERAPEUTICS INC - GLEN FARMER, CHIEF FINANCIAL
OFFICER,
IS CONTINUING IN HIS POSITION WITH COMPANY
Source text for Eikon: ID:nGNX95Vx4G
Further company coverage: IMUN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biostax
See all newsBrief: Biostax Corp Announces Voluntary Delisting From Otc Pink Market And SEC Deregistration
Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
Brief: Immune Therapeutics Inc Announces Management Change
Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors